Citations 1
Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Gökbuget, Nicola , Kantarjian, Hagop M. , Brüggemann, Monika , Stein, Anthony S. , Bargou, Ralf C. , Dombret, Hervé , Heffner, Leonard T., Rigal‐Huguet, Françoise , Litzow, Mark R. , Gao, Shan , Nagorsen, Dirk , Forman, Stephen J. , Topp, Max S. , Kantarjian, Hagop , Fielding, Adele K. , O’Brien, Susan , Zugmaier, Gerhard
Blood Advances | October 21, 2019 | Volume: 3 | Issue: 20 | Pages: 3033-3037
10.1182/bloodadvances.2019000457
Key Points MRD response has value as a prognostic factor for blinatumomab treatment in R/R B-cell precursor ALL. MRD response was associated with better outcomes in terms of OS and RFS in blinatumomab-treated R/R ALL.